Pfizer stock: BofA raises target to USD 29 for Pfizer stock

Published on 10/23/2026 at 16:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer reports third-quarter results on November 3, 2026. Pfizer stock costs EUR 26.81 on October 23, 2026, down 0.89 percent versus the Xetra close.

BofA target revision

BofA raised its Pfizer target from USD 27.00 to USD 29.00 on October 9, 2026.
Pfizer scheduled its next results for November 3, 2026.
Pfizer stock costs EUR 26.81 at Lang & Schwarz on October 23, 2026 at 4:09 p.m. CEST, 0.89 percent below the Xetra close of October 22, 2026 and 1.11 percent below its 52-week high.

Bauhaus-Poster mit geometrischen Formen und Schriftzug PHARMA, Symbolbild für Pfizer Inc — Geometrisches Bauhaus-Poster mit dem Wort PHARMA visualisiert die Branche von Pfizer Inc., ISIN US7170811035, künstlerisch, Illustration mit AI erstellt.

Bank of America analyst Jason Gerberry raised Pfizer's price target from USD 27.00 to USD 29.00 on October 9, 2026, while keeping a Neutral rating, according to Markets Insider. Pfizer stock was trading at EUR 26.81 at Lang & Schwarz on October 23, 2026 at 4:09 p.m. CEST, down 0.89 percent versus the Xetra close of October 22, 2026 at EUR 27.05.

Target rises as risks remain

The new USD 29.00 target is 4.59 percent below Pfizer's USD 30.40 NYSE price on October 22, 2026. The target change therefore improves the analyst view without placing the stock above the latest US quotation.

Cantor Fitzgerald also maintained a Neutral rating while raising its target from USD 27.00 to USD 28.00 on October 8, 2026. The firm said Pfizer remained dependent on the MEVPRO-1 readout and cited questions about longer-term growth and dividend sustainability, as reported by Investing.com.

Stock near its yearly high

The euro quotation sits EUR 0.30 below its 52-week high of EUR 27.11 and EUR 6.09 above its 52-week low of EUR 20.72. The range and the price are dated October 23, 2026, giving the current move a clear position within the past year. The quotation was below the Xetra close even as the stock remained 1.11 percent below its yearly high.

Results date sets the next checkpoint

Pfizer has scheduled its next results and analyst conference call for November 3, 2026, according to the company's October 2026 communications on Pfizer. The date gives investors a defined point for testing the assumptions behind the revised targets.

Pfizer stock remains below its high

Pfizer's market capitalization was USD 173.2 billion on October 22, 2026, while its price-to-earnings ratio was 40.20 on October 23, 2026. On the same October 23 session, Johnson & Johnson traded at USD 262.95 with a market capitalization of USD 633.7 billion and a price-to-earnings ratio of 39.92; Merck & Co. traded at USD 143.83 with a market capitalization of USD 354.9 billion and a price-to-earnings ratio of 115.30.

Pfizer stock was trading at EUR 26.81 at Lang & Schwarz on October 23, 2026 at 4:09 p.m. CEST, 0.89 percent below the Xetra close of October 22, 2026 at EUR 27.05. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.